Eterna Therapeutics Inc. (ERNA) AI Stock Analysis
ERNA AI stock analysis summary
AI ResearchEterna Therapeutics Inc. (ERNA) is a clinical-stage biotechnology company developing messenger RNA (mRNA) cell engineering technologies. The business operates with minimal commercial revenue, generating $1,000 in trailing twelve months revenue with an annual revenue CAGR of -51.3% from FY2017 to FY2024. As of June 30, 2026, the company held $5.0M in cash and short-term investments alongside a net cash position of $4.7M.
- Market cap
- $3.4M
- Revenue (TTM)
- $1,000
- P/E
- —
- 1Y return
- -93.3% S&P 500 16.8%
- Avg. target
- $30.00 1335.4% vs last close
Bull case
- Eterna Therapeutics maintains a positive net cash balance of $4.7M as of June 30, 2026, with a low debt-to-equity ratio of 0.11.
- The lone covering analyst maintains a Strong Buy rating with a $30.00 mean price target, representing a 1335.4% upside to the $2.09 share price.
- Consensus estimates project net loss per share to improve by 89.7% in the next fiscal year, moving from -$18.02 to -$1.86.
Bear case
- The stock has collapsed 93.3% over the past year and 100.0% over the trailing 5-year period.
- Trailing twelve months revenue totaled just $1,000 following a 94.1% year-over-year revenue decline in the quarter ended June 30, 2026.
- Significant cash burn persisted through FY2024, with free cash flow of -$16.2M alongside a 581.8% expansion in share count over 5 years.
What Eterna Therapeutics does
Eterna Therapeutics Inc. specializes in advancing messenger RNA (mRNA) cell engineering technologies designed to rectify cellular dysfunction and target diverse therapeutic indications. Its portfolio includes Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. These platforms aim to enable novel cell therapy and gene-editing approaches, with an emphasis on oncology, blood disorders, and monogenic diseases. Originally known under a previous name, the Cambridge, Massachusetts-based company rebranded in October 2022 and maintains a workforce of 5 employees.
Growth and profitability
Top-line performance has contracted substantially, marked by a 5-year revenue CAGR of -51.3% between FY2017 and FY2024. Revenue declined from $23.3M in FY2018 to $68,000 in FY2023, before rebounding slightly to $582,000 in FY2024 with a gross margin of 83.5%. However, net losses expanded to -$44.5M in FY2024, resulting in a net margin of -7652.7% and an operating margin of -2693.1%. For the latest quarter ended June 30, 2026, quarterly revenue growth fell 94.1% year-over-year, leaving trailing twelve months revenue at $1,000 and an eps_ttm of -$13.63.
Balance sheet and cash flow
As of June 30, 2026, Eterna Therapeutics held $5.0M in cash and short-term investments against total debt of $349,000, yielding net cash of $4.7M. The balance sheet shows total assets of $6.3M, shareholders' equity of $3.2M, a current ratio of 2.01, and a debt-to-equity ratio of 0.11. Operating cash flow in FY2024 stood at -$15.8M with free cash flow of -$16.2M. Capital expenditures were $37,000 in FY2025, while the share count increased 581.8% over the past 5 years.
Valuation and performance
With a market capitalization of $3.4M and an enterprise value of -$362,568, Eterna Therapeutics trades at a price-to-sales ratio of 7.2x and a price-to-book ratio of 1.3x. By comparison, the median of its US-listed Healthcare peers trades at a price-to-sales ratio of 4.1x and an ev_to_ebitda of 12.0x. ERNA shares have retreated 93.3% over the past 1 year and 100.0% over 5 years, compared to gains of 16.8% and 83.0% for the S&P 500 (SPY) over the same periods.
What analysts expect
One analyst covers Eterna Therapeutics, posting a Strong Buy rating with 0 Buy, Hold, Sell, or Strong Sell recommendations. The mean price target is $30.00, representing a 1335.4% premium over the last close of $2.09. Projections include an eps estimate of -$18.02 and $0 in revenue for the fiscal year ending December 31, 2026, followed by an eps estimate of -$1.86 and $0 in revenue next fiscal year. The company recorded 0 eps beats over the last 4 quarters, and its next earnings date is November 6, 2026.
Key risks and what to watch
- The company generated only $1,000 in trailing twelve months revenue, while consensus revenue estimates sit at $0 through next fiscal year.
- Cash resources of $5.0M as of June 30, 2026, face ongoing pressure from operational cash consumption, which stood at -$15.8M in FY2024.
- A 581.8% increase in share count over 5 years highlights ongoing shareholder dilution to support operations.
- High market volatility is evident from a beta of 2.65, with shares trading 76.3% below their 200-day moving average.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this ERNA AI stock analysis
This page is an AI-written research summary of Eterna Therapeutics Inc. (ERNA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: ERNA income statement, ERNA balance sheet, ERNA key metrics, ERNA analyst forecast, ERNA chart. See the ERNA stock overview for the latest quote and news.
ERNA AI stock analysis FAQ
What does Eterna Therapeutics Inc. do?
Eterna Therapeutics Inc. develops mRNA cell engineering technologies, including Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming, targeting oncology, blood disorders, and monogenic diseases.
What is Eterna Therapeutics' cash position?
As of June 30, 2026, the company held $5.0M in cash and short-term investments, total debt of $349,000, and net cash of $4.7M.
What are analysts forecasting for ERNA?
The single covering analyst rates the stock a Strong Buy with a price target of $30.00. Forecasts call for an EPS of -$18.02 on $0 revenue in FY2026 and an EPS of -$1.86 on $0 revenue in FY2027.
Does Eterna Therapeutics pay a dividend?
No, Eterna Therapeutics does not pay a dividend.
When is the next earnings report for ERNA?
The next earnings date for Eterna Therapeutics is scheduled for November 6, 2026.